KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer

Share :
Published: 18 Dec 2019
Views: 1873
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Prof Peter Schmid speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the recent results from the KEYNOTE-522 study.

This was a study of neoadjuvant pembrolizumab and chemo vs placebo and chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer.

Prof Schmid provides a detailed look at the results and discusses what further analyses might be undertaken.

Watch the press conference here

Read more about the study here